Diagnostic Microdosing Approach to Study Gemcitabine Resistance

Scharadin, Tiffany M.; Zhang, Hongyong; Zimmermann, Maike; Wang, Sisi; Malfatti, Michael A.; Cimino, George D.; Turteltaub, Kenneth; de Vere White, Ralph; Pan, Chong-xian; Henderson, Paul T.

doi:10.1021/acs.chemrestox.6b00247

Diagnostic Microdosing Approach to Study Gemcitabine Resistance

Journal Article · Thu Sep 22 00:00:00 EDT 2016 · Chemical Research in Toxicology

DOI:https://doi.org/10.1021/acs.chemrestox.6b00247· OSTI ID:1438650

Scharadin, Tiffany M. ^[1]; Zhang, Hongyong ^[1]; Zimmermann, Maike ^[2]; Wang, Sisi ^[1]; Malfatti, Michael A. ^[3]; Cimino, George D. ^[4]; Turteltaub, Kenneth ^[3]; de Vere White, Ralph ^[5]; Pan, Chong-xian ^[2]; Henderson, Paul T. ^[2]

Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. Division of Hematology and Oncology
Univ. of California Davis, Sacramento, CA (United States). Dept. of Internal Medicine. Division of Hematology and Oncology; Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States)
Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States). Biosciences and Biotechnology Division
Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States)
Univ. of California Davis Medical Center, Sacramento, CA (United States). Dept. of Urology

Gemcitabine metabolites cause the termination of DNA replication and induction of apoptosis. In this paper, we determined whether subtherapeutic “microdoses” of gemcitabine are incorporated into DNA at levels that correlate to drug cytotoxicity. A pair of nearly isogenic bladder cancer cell lines differing in resistance to several chemotherapy drugs were treated with various concentrations of ¹⁴C-labeled gemcitabine for 4–24 h. Drug incorporation into DNA was determined by accelerator mass spectrometry. A mechanistic analysis determined that RRM2, a DNA synthesis protein and a known resistance factor, substantially mediated gemcitabine toxicity. Finally, these results support gemcitabine levels in DNA as a potential biomarker of drug cytotoxicity.

View Accepted Manuscript (DOE)

Research Organization:: Accelerated Medical Diagnostics Incorporated, Berkeley, CA (United States); Lawrence Livermore National Lab. (LLNL), Livermore, CA (United States); Univ. of California Davis, Sacramento, CA (United States)

Sponsoring Organization:: Dept. of Veterans Affairs (VA) (United States); National Inst. of Health (NIH) (United States); USDOE

Grant/Contract Number:: AC52-07NA27344

OSTI ID:: 1438650

Report Number(s):: LLNL-JRNL--737043

Journal Information:: Chemical Research in Toxicology, Journal Name: Chemical Research in Toxicology Journal Issue: 11 Vol. 29; ISSN 0893-228X

Publisher:: American Chemical Society (ACS)Copyright Statement

Country of Publication:: United States

Language:: English

References (24)

A microdosing approach for characterizing formation and repair of carboplatin-DNA monoadducts and chemoresistance Henderson, Paul T.; Li, Tao; He, Miaoling International Journal of Cancer, Vol. 129, Issue 6 https://doi.org/10.1002/ijc.25814	journal	March 2011
Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC Lanz, Christian; Früh, Martin; Thormann, Wolfgang Journal of Separation Science, Vol. 30, Issue 12 https://doi.org/10.1002/jssc.200600534	journal	August 2007
2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines Ruiz van Haperen, Veronique W. T.; Veerman, Gijsbert; Vermorken, Jan B. Biochemical Pharmacology, Vol. 46, Issue 4 https://doi.org/10.1016/0006-2952(93)90566-F	journal	August 1993
Accelerator Mass Spectrometry for Biomedical Research Brown, Karen; Dingley, Karen H.; Turteltaub, Kenneth W. Methods in Enzymology https://doi.org/10.1016/S0076-6879(05)02014-8	book	January 2005
Prognostic and Prediction Tools in Bladder Cancer: A Comprehensive Review of the Literature Kluth, Luis A.; Black, Peter C.; Bochner, Bernard H. European Urology, Vol. 68, Issue 2 https://doi.org/10.1016/j.eururo.2015.01.032	journal	August 2015
Pharmacogenomics in bladder cancer Dancik, Garrett M.; Theodorescu, Dan Urologic Oncology: Seminars and Original Investigations, Vol. 32, Issue 1 https://doi.org/10.1016/j.urolonc.2013.09.007	journal	January 2014
A High-Throughput Method for the Conversion of CO ₂ Obtained from Biochemical Samples to Graphite in Septa-Sealed Vials for Quantification of ¹⁴ C via Accelerator Mass Spectrometry Ognibene, Ted J.; Bench, Graham; Vogel, John S. Analytical Chemistry, Vol. 75, Issue 9 https://doi.org/10.1021/ac026334j	journal	May 2003
Quantification of Gemcitabine Incorporation into Human DNA by LC/MS/MS as a Surrogate Measure for Target Engagement Wickremsinhe, Enaksha R.; Lutzke, Barry S.; Jones, Barry R. Analytical Chemistry, Vol. 82, Issue 15 https://doi.org/10.1021/ac100984h	journal	August 2010
Kinetics of Carboplatin−DNA Binding in Genomic DNA and Bladder Cancer Cells As Determined by Accelerator Mass Spectrometry Hah, Sang Soo; Stivers, Kristen M.; de Vere White, Ralph W. Chemical Research in Toxicology, Vol. 19, Issue 5 https://doi.org/10.1021/tx060058c	journal	May 2006
Gemcitabine Causes Minimal Modulation of Carboplatin-DNA Monoadduct Formation and Repair in Bladder Cancer Cells Wang, Sisi; Zhang, Hongyong; Malfatti, Michael Chemical Research in Toxicology, Vol. 23, Issue 11 https://doi.org/10.1021/tx1003547	journal	November 2010
The future of bladder cancer care in the USA Kaplan, Alan L.; Litwin, Mark S.; Chamie, Karim Nature Reviews Urology, Vol. 11, Issue 1 https://doi.org/10.1038/nrurol.2013.180	journal	August 2013
Increased sensitivity to gemcitabine of P-glycoprotein and multidrug resistance-associated protein-overexpressing human cancer cell lines Bergman, A. M.; Pinedo, H. M.; Talianidis, I. British Journal of Cancer, Vol. 88, Issue 12 https://doi.org/10.1038/sj.bjc.6601011	journal	June 2003
Mechanisms of synergism between cisplatin and gemcitabine in ovarian and non-small-cell lung cancer cell lines Moorsel, C. J. A. van; Pinedo, H. M.; Veerman, G. British Journal of Cancer, Vol. 80, Issue 7 https://doi.org/10.1038/sj.bjc.6690452	journal	May 1999
Cellular pharmacology of gemcitabine Mini, E.; Nobili, S.; Caciagli, B. Annals of Oncology, Vol. 17 https://doi.org/10.1093/annonc/mdj941	journal	May 2006
Current perspectives in bladder cancer management Griffiths, T. R. L. International Journal of Clinical Practice, Vol. 67, Issue 5 https://doi.org/10.1111/ijcp.12075	journal	November 2012
Validation study of the prediction system for clinical response of M-VAC neoadjuvant chemotherapy Takata, Ryo; Katagiri, Toyomasa; Kanehira, Mitsugu Cancer Science, Vol. 98, Issue 1 https://doi.org/10.1111/j.1349-7006.2006.00366.x	journal	January 2007
New insights into the pharmacology and cytotoxicity of gemcitabine and 2′,2′-difluorodeoxyuridine Veltkamp, Stephan A.; Pluim, Dick; van Eijndhoven, Maria A. J. Molecular Cancer Therapeutics, Vol. 7, Issue 8 https://doi.org/10.1158/1535-7163.MCT-08-0137	journal	August 2008
Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells Iwasaki, Hiromichi; Huang, Peng; Keating, Michael J. Blood, Vol. 90, Issue 1 https://doi.org/10.1182/blood.V90.1.270	journal	July 1997
Differential Incorporation of Ara-C, Gemcitabine, and Fludarabine Into Replicating and Repairing DNA in Proliferating Human Leukemia Cells Iwasaki, Hiromichi; Huang, Peng; Keating, Michael J. Blood, Vol. 90, Issue 1 https://doi.org/10.1182/blood.V90.1.270.270_270_278	journal	July 1997
Recent advances in the diagnosis and treatment of bladder cancer Cheung, Grace; Sahai, Arun; Billia, Michele BMC Medicine, Vol. 11, Issue 1 https://doi.org/10.1186/1741-7015-11-13	journal	January 2013
Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer Wang, Sisi; Zhang, Hongyong; Scharadin, Tiffany M. PLOS ONE, Vol. 11, Issue 1 https://doi.org/10.1371/journal.pone.0146256	journal	January 2016
Bladder cancer pharmacogenomics: recent insights and future perspectives O’Donnell, Peter H. Pharmacogenomics, Vol. 13, Issue 14 https://doi.org/10.2217/pgs.12.145	journal	November 2012
Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer Cimino, George D.; Pan, Chong-xian; Henderson, Paul T. Bioanalysis, Vol. 5, Issue 3 https://doi.org/10.4155/bio.12.325	journal	February 2013
Optimizing Systemic Therapy for Bladder Cancer Pal, Sumanta K.; Milowsky, Matthew I.; Plimack, Elizabeth R. Journal of the National Comprehensive Cancer Network, Vol. 11, Issue 7 https://doi.org/10.6004/jnccn.2013.0101	journal	July 2013

Cited By (2)

DHS (trans−4,4′-dihydroxystilbene) suppresses DNA replication and tumor growth by inhibiting RRM2 (ribonucleotide reductase regulatory subunit M2) Chen, Chi-Wei; Li, Yongming; Hu, Shuya Oncogene, Vol. 38, Issue 13 https://doi.org/10.1038/s41388-018-0584-6	journal	December 2018
Radiocarbon Tracers in Toxicology and Medicine: Recent Advances in Technology and Science Malfatti, Michael A.; Buchholz, Bruce A.; Enright, Heather A. Toxics, Vol. 7, Issue 2 https://doi.org/10.3390/toxics7020027	journal	May 2019

Similar Records

Microdose-Induced Drug–DNA Adducts as Biomarkers of Chemotherapy Resistance in Humans and Mice

Journal Article · Tue Nov 29 19:00:00 EST 2016 · Molecular Cancer Therapeutics · OSTI ID:1410044

A diagnostic microdosing approach to investigate platinum sensitivity in non-small cell lung cancer

Journal Article · Sun Apr 23 20:00:00 EDT 2017 · International Journal of Cancer · OSTI ID:1438672

Molecular Dissection of Induced Platinum Resistance through Functional and Gene Expression Analysis in a Cell Culture Model of Bladder Cancer

Journal Article · Thu Jan 21 19:00:00 EST 2016 · PLoS ONE · OSTI ID:1259484

Related Subjects

60 APPLIED LIFE SCIENCES

Diagnostic Microdosing Approach to Study Gemcitabine Resistance

Citation Formats

References (24)

Cited By (2)

Similar Records

Related Subjects